« November 2006 | Main | January 2007 »

December 2006

December 22, 2006

100th Post!

Digg! digg it! del.icio.us

Wow, 6 months and I'm already up to 100 posts. Thanks for following along, everyone - it's been some fun putting this site together. Hopefully, you've enjoyed what you've seen so far and maybe even learned something along the way.

After today, StLBiotech.com is going on a much-needed holiday break. Don't worry, I'll be back on January 2nd with a shiny new set of biotech stories for the new year. Until then, I leave you with a very special holiday-themed link of the week, courtesy of the elves over on Mythbusters:

December 21, 2006

Two Missouri Lawmakers Announce Anti-Cloning Efforts

Digg! digg it! del.icio.us

Just as I was starting to wonder why anti-Amendment 2 ads were still showing up on cable, yesterday some answers started to crop up. In a joint statement, two state Republican lawmakers, Rep. Jim Lembke of St. Louis and Sen. Matt Bartle of Lee's Summit announced that next year they would begin a push to replace the recently-passed stem cell research protection amendment with one that bans all forms of human cloning.

Both men believe the voters to have been "decieved" in November and that the general public is actually deeply opposed to therapeutic cloning. Said Rep. Lembke:

"We believe overwhelmingly that people across Missouri want to ban all human cloning, and want that to be in our constitution"

All I have to say is: scoreboard. The vote came in, and 51% of the state agreed to support the cloning ban within Amendment 2. It seems like I'm not alone in my sentiment either - Some friendly faces:

Governer Matt Blunt (R):

"My position on this is well-known. I don't see a need for another constitutional amendment."

State Sen. Chris Koster (R-Harrisonville):

"It should have closed the book on the issue. The General Assembly is respectful of the voters' wishes."

"Sen. Bartle wants Missouri to secede from the union of states that allow full scientific research and to join the minority that do not."

Missouri Coalition for Lifesaving Cures Spokeswoman Connie Farrow:

"The voters knew what they were voting on. It's reprehensible that they would suggest voters were ill-informed."

The new amendment will begin as a stricly legislative effort. However, if that proves unsuccessful supporters have indicated that they would be open to collecting signatures for another ballot initiative.

Links:

December 20, 2006

Singulex Publishes Data on Bioassay Performance

Digg! digg it! del.icio.us

As reported by the St. Louis Biobelt, on December 6th Singulex, an early-stage bioassay firm with R&D labs in the Center for Emerging Technologies, reported positive data from their Erenna™ system in Clinical Chemistry. The assay is for the detection of biomarkers, proteins or other small molecules present in various body fluids like plasma that can help diagnose disease. In this case, the Singulex team is interested in a biomarker for heart attacks, or Acute Myocardial Infarction.

The novelty here is in the detection range. Since their assay works on such small scales, the Erenna results indicated that the test could detect sub-picogram changes in biomarker levels, important for good disease diagnosis.

The Erenna system is slated to become commercially available in early 2007.

December 19, 2006

Express Scripts Makes Hostile Takeover Bid for Rival

Digg! digg it! del.icio.us


In news already shaking the perscription drug industry, the New York Times reported yesterday on a hostile takeover bid by Maryland Heights-based Express Scripts for one of their rivals, Caremark Rx. Both firms are in the business of benefits management, a sort of middleman between pharmaceutical companies and large businesses who want to offer perscription drug discounts to their employees.

The reported $26 Billion bid bests a competing offer by the CVS drugstore chain, and would create the largest organization of its kind in the nation. In many ways, the bid was a surprise to many analysts. Because of its relatively small size, Express Scripts was thought to be a more probable acquisition target than anything else. That could still happen, with large firms like Walgreen's eager to boost their pharmacy services. Regardless, if today's activities continue, it could change the way drugs are sold in this country in a big way.

December 18, 2006

Monsanto, Other Biotechs Among St. Louis RCGA "Top 50" Award Winners

Digg! digg it! del.icio.us

Last week, the December issue of St. Louis Commerce magazine included the 10th annual Greater St. Louis Top 50 Award winners. The list, assembled by the St. Louis RCGA, began in 1996 as a way to recognize technology companies for "overall business success and in their ability to positively affect the future of the business community".

Since then, the award winners have included companies in other fields, but this year's list includes a number of biotech firms:

In addition, Monsanto was awarded the 2006 Boeing Corporate Citizen Award for their charitable and regional development work.

The list's corporate sponsors includes Sigma-Aldrich, a local biotech leader in of themselves.

December 15, 2006

Cool Link of the Week: Google Patent

Digg! digg it! del.icio.us

The cool link of this week is Google Patent, a Web 2.0-ish interface for browsing the USPTO database. After years of putting up with the mind-numbingly slow load times of the governmental site, this new, smooth-as-silk interface is worthy of mention.

One note: As of this writing, Google Patents doesn't allow printing from their site. If you're interested in obtaining easy-to-use copies of the documents, I'd recommend writing down the publication number and using pat2pdf.org, a free pdf-conversion utility.

December 14, 2006

It's "Patently" Obvious

Digg! digg it! del.icio.us


The other big story from last week was the Supreme Court hearing arguments in KSR International v. Teleflex, Inc., the 3rd major patent case this year. At stake is the "obvious" test, a legal technique devised in the early 80's to decide if ideas are original enough to deserve patent protection.

Here's the quick version: Imagine you're an inventor, and one day in a burst of creativity you discover a box that can make water...out of thin air! It's great, and you impress your friends at parties, and someone suggests you file for patent protection. The next day, you're browsing the refrigerators at Lowe's and inspiration strikes again: Magic box + freezer = free ice!

Both of those are new ideas, but most people would probably agree that the second one should win a fewer awards than the first. Ira Flatow compared it to a double-play, since the principles are the same as throwing to first. It's obvious, and probably doesn't deserve as strict a level of protection.

However, beginning in 1982 the courts began to apply a more rigid set of rules to define "obviousness" more exactly. Were there published documents or public discussions describing your idea prior to when you thought of it? Not obvious. But if the your concept is less clearly described elsewhere, the courts have been inclined to let the patents through.

The arguments last week seem to suggest that the Supreme Court is leaning towards loosening up the obviousness test. At one point, Justice Scalia, described the test as "gobbledygook" and "meaningless", and Chief Justice Roberts, the big kidder, asked:

"Who do you get to be an expert to tell us something's not obvious?" -Laughter- "The least insightful person you can find?"

This is a big deal for IP-heavy industries like pharma or biotech, where drugs are often issued patent protection for a variety of uses and combinations. Would a more permissive obviousness test promote new technology development, or just hurt their bottom lines? The Supreme Court is set to issue an opinion on the case by next July.

Links:

December 13, 2006

New Biotech-Focused Law Firm

Digg! digg it! del.icio.us

As reported in the Post-Dispatch, recently a group of lawyers formerly of the St. Louis office of Sonnenschein Nath & Rosenthal LLP announced the opening of Biotactica LLC, a firm specializing in biotech IP. The team, Kevin Buckley, Tara Nealey and Saul Zackson, all have extensive science backgrounds (Dr. Buckley and Dr. Zackson have PhD's in Physiology and Molecular Biology, respectively).

According to their website, the new firm will help life science startups help move their ideas more quickly down the development pipeline:

Biotactica assists its clients in accelerating biotechnology and life science innovations from discovery to market by integrating legal practices including intellectual property protection, licensing, regulation, funding and marketing. In doing so, Biotactica partners its clients with contract research organizations, venture capitalists, strategic consultants and other commercial entities.

Biotactica is headquartered in Creve Coeur.

December 12, 2006

Pfizer Troubles, pt. 2

Digg! digg it! del.icio.us
As reported everywhere, last week Pfizer announced the cancellation of their potentially blockbuster new cholesterol medication Torcetrapib. Without this mega drug in their pipeline, and the patent protection for Lipitor ceasing at the end of this decade, what's in the future for Pfizer?

Lot's of opinions on this one. Pfizer itself was the first up, announcing that despite the big setback they still have more than 240 development programs in 11 therapeutic areas, more than enough science to keep their pipeline flowing.

But what if those don't work out either? Some analysts have predicted that the life science behemoth will begin to transform into something of an portfolio manager, letting other companies or non-profits handle the R&D and then sweeping down to license or acquire the resulting IP. Indeed, one of the most universally-accepted ideas is that Pfizer will have to buy something to fill out its development schedule. Others have suggested a mega-merger with another major Pharma developer, though with Pfizer's already-enormous size, it's uncertain how the market might respond to this.

Moreover, what will be the effect on the biotech sector as a whole? One of the drivers of small-capital biotech investment has always been the willingness of big pharma units to buy the results on the back end. Indeed, many startups founders have defined their exit strategies as "do science for a bit, sell company to Pfizer, retire to Cozumel". Paul Kedrosky had a pertinent column wondering if Pfizer, after spending $800 million and assembing an all-star team of scientists and lobbyists can't push through a final product, what are the chances anyone else can? These trial failures happen nearly 50% of the time, so this isn't a rare event.

Regardless, some changes are ahead. Two weeks ago, the company announced plans to cut their sales staff by 2,200 members in a cost-saving move. It's unlikely they'll be the only ones feeling the pain in the months to come.

December 11, 2006

Conan Earns His Geek Cred

Digg! digg it! del.icio.us

Someone sent me a great link today. See, if Donny Osmond can do it, how hard can science really be?

Conan O'Brien hosts "Biochemistry with the Stars"

Pfizer Cancels Torcetrapib Phase-III Trials

Digg! digg it! del.icio.us

The big news from last week was Pfizer's announcement on Monday that, due to "disappointing" mortality data, the company will be canceling their ongoing phase-III clinical trials for Torcetrapib, a new cholesterol pharmaceutical. The importance of this really can't be understated.

Currently, Pfizer is the world's #1 drug maker due in a large part to the success of Lipitor (Atorvastatin), another anti-cholesterol medication predicted to bring in nearly $13 billion in revenue this year. Unfortunately for the company, the formulation's patent protection is due to expire in 2010, allowing generic competition to officially begin in the US. To counter this, recent years have seen Pfizer developing combination therapies, such as Caduet to extend the novelty of the drug.

This study examined one of these packages, a mixture of Lipitor and the newly-developed Torcetrapib. Hopes were very high for the trials, with many analysts in the industry more-or-less expecting this to be the blockbuster drug of the next decade.

The cancellation raises a lot of questions about Pfizer's drug development process, and the health of the pharmaceutical industry as a whole. More on this next time, but for now, here are some links:

December 8, 2006

StL Biotech Among IdeaBounce Winners!

Digg! digg it! del.icio.us

Thanks everyone for all of the support last night. It really means a lot to be recognized for something I've put a lot of time into. All of the teams were great, and the other winners really deserved the acclaim:

If you've just discovered StL Biotech don't worry, I haven't run away. New posts will be returning Monday. As always, I welcome any comments or suggestions you might have.

December 4, 2006

IdeaBounce

Digg! digg it! del.icio.us

This Thursday, the Wash U Skandalaris Center is hosting their winter IdeaBounce, featuring the likes of......me. IdeaBounce is a chance for individuals, both affiliated with the school and not, to pitch their ideas to an audience of entrepreneurs and venture developers. Each presentation lasts for 2 minutes, and at the end of the night 5 winners are awarded a $100 prize and a dinner meeting with the judges. (Hopefully they won't just charge the winners $100 for the food)

Needless to say, I'm a little excited. Hope to see you there on Thursday!

December 3, 2006

Bioenergy Lecture at Wash U

Digg! digg it! del.icio.us

On Wednesday, the Academy of Science and Skandalaris Center hosted a very interesting lecture on the prospects for renewable bio-energy. Speaking were Dr. Lars Angenent, Assistant Professor of Energy, Environmental, and Chemical Engineering at Wash U, and Nick Akers, President of Akermin, Inc. The presentations covered both the larger need for renewable energy and how their teams are approaching the problem, and the whole event reminded me of several lectures I heard in San Diego last year.


Dr. Lars Angenent

Both speakers are approaching bioenergy from different angles. Dr. Angenent's team specializes in Microbial Fuel Cells (MFC's), battery-type devices that use microbe-covered electrodes to generate energy. One big plus of this approach is its adaptability for a huge range of fuels. In fact, the Wash U group, and many others, are interested in generating electricity from urban sewage, not a small prospect considering wastewater treatment can make up as much as 50% of urban power consumption in the U.S.

Akermin is interested in an entirely different goal: high-efficiency alcohol-fueled devices to compete with consumer lithium-ion batteries. Instead of growing colonies of electron-spitting microbes in their fuel cells, Nick Akers and his team attach electrochemically active proteins to carbon electrodes, increasing the energy yield per surface area.

People have talked about bioenergy devices for at least 20 years, partly because the idea is just cool, but also because it syncs up with what we see in nature. By far the most efficient solar-cells on the planet are the chloroplasts in a common weed; the muscle in my little finger has a better power conversion than the most advanced auto engine. But it’s also important to remember that the cells and proteins we try to harness for industry have spent millions of years optimizing themselves, not for use in batteries, but survival.

Why does this matter? The products that these bio-devices are aiming to replace, namely traditional metal and ceramic batteries, have their own problems. However, energy yield per square inch of electrode isn't one of them (Pt-Oxygen fuel cells have a very favorable reducing potential, they just cost a lot). The direction that biotech always wins, though, is in flexibility. How many car batteries could operate off of sewage, or oil spills, or the glucose in human blood?

For all I know, Akermin and Wash U have already made bio-fuel cells that can outpace their metal counterpoints. Even if they haven't, though, the idea of producing energy from biological materials is one with enormous potential.

On a side note, Nick Akers also took the opportunity to talk about the new Center for Evergreen Energy, announced at the recent DOE Renewable Energy Conference. Worth keeping an eye on.

The opinions expressed herein are soley those of the author and do not represent the views of any other individual or group, unless expressely stated.
Copyright © 2006-2007, Brian Loyal. All rights reserved